Analyzing Microbot Medical (NASDAQ:MBOT) and Autolus Therapeutics (NASDAQ:AUTL)


Share on StockTwits

Microbot Medical (NASDAQ:MBOT) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Volatility & Risk

Microbot Medical has a beta of 4.09, meaning that its share price is 309% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

Earnings & Valuation

This table compares Microbot Medical and Autolus Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Microbot Medical N/A N/A -$7.25 million N/A N/A
Autolus Therapeutics $2.91 million 158.19 -$123.85 million ($2.88) -3.06

Microbot Medical has higher earnings, but lower revenue than Autolus Therapeutics.

Institutional and Insider Ownership

9.0% of Microbot Medical shares are held by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are held by institutional investors. 8.7% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Microbot Medical and Autolus Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Microbot Medical N/A -28.95% -26.60%
Autolus Therapeutics -8,652.90% -54.01% -44.19%

Analyst Ratings

This is a summary of recent ratings and price targets for Microbot Medical and Autolus Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical 0 0 1 0 3.00
Autolus Therapeutics 0 0 8 0 3.00

Microbot Medical currently has a consensus target price of $20.00, indicating a potential upside of 152.53%. Autolus Therapeutics has a consensus target price of $24.00, indicating a potential upside of 172.42%. Given Autolus Therapeutics’ higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Microbot Medical.

Summary

Microbot Medical beats Autolus Therapeutics on 6 of the 10 factors compared between the two stocks.

Microbot Medical Company Profile

Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 37 issued/allowed patents and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.